Previous 10 | Next 10 |
Harrow Health, Inc. (HROW) Q4 2021 Earnings Conference Call March 10, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Participants...
Harrow Health press release (NASDAQ:HROW): Q4 GAAP EPS of -$0.27 misses by $0.23. Revenue of $20.2M (+38.4% Y/Y) beats by $0.84M. For further details see: Harrow Health GAAP EPS of -$0.27 misses by $0.23, revenue of $20.2M beats by $0.84M
Sixth Consecutive Quarter of Record Revenues Highlights for Fourth Quarter 2021: Record revenues of $20.2 million, a 38% increase compared with $14.6 million for the prior‑year quarter; Gross profit was a record $15.1 million, a 42% increase compared with $10.7 ...
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings 20 years of extensive finance and accounting experien...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fo...
The U.S. Food and Drug Administration (FDA) accepted Harrow Health's (NASDAQ:HROW) application seeking approval of AMP-100, an ocular surface anesthesia and intraoperative pain management during eye surgery. The FDA is expected to make a decision on the new drug application by Oct. ...
Receives PDUFA Date of October 16, 2022 Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company’s ...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25,...
SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. Our portfolio is in no way comparable to an index and will not follow any in harmony. We were/are in the process of turning over a considerable portion of the portfolio into new ...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com . The report focuses on Harrow Healt...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...